Perspective Therapeutics annual debt-to-equity ratio
2020
2021
2022
2022
2023
2024
2025
Perspective Therapeutics Debt-to-Equity Ratio Growth & History (CATX)
Perspective Therapeutics's debt-to-equity ratio was 0.02 for fiscal 2025.
View full Perspective Therapeutics company overviewPerspective Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.02 | 0.00 | +12.44% |
| 2024 | 2024-12-31 | 0.01 | −0.02 | −58.82% |
| 2023 | 2023-12-31 | 0.03 | 0.03 | +372.99% |
| 2022 · Dec 31 | 2022-12-31 | 0.01 | — | — |
| 2022 · Jun 30 | 2022-06-30 | 0.01 | −0.00 | −25.72% |
| 2021 | 2021-06-30 | 0.01 | −0.16 | −93.44% |
| 2020 | 2020-06-30 | 0.18 | — | — |
Perspective Therapeutics quarterly debt-to-equity ratio
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.01 | −0.00 | −8.90% |
| Q1 2026 | 2026-03-31 | 0.01 | −0.00 | −9.21% |
| Q4 2025 | 2025-12-31 | 0.02 | 0.00 | +12.44% |
| Q3 2025 | 2025-09-30 | 0.01 | 0.00 | +5.27% |
| Q2 2025 | 2025-06-30 | 0.01 | 0.00 | +18.21% |
| Q1 2025 | 2025-03-31 | 0.01 | 0.00 | +7.14% |
| Q4 2024 | 2024-12-31 | 0.01 | −0.02 | −58.82% |
| Q3 2024 | 2024-09-30 | 0.01 | −0.02 | −61.18% |
| Q2 2024 | 2024-06-30 | 0.01 | −0.01 | −52.09% |
| Q1 2024 | 2024-03-31 | 0.01 | −0.01 | −30.20% |
| Q4 2023 | 2023-12-31 | 0.03 | 0.03 | +372.99% |
| Q3 2023 | 2023-09-30 | 0.03 | 0.03 | +321.70% |
| Q2 2023 | 2023-06-30 | 0.02 | 0.02 | +177.36% |
| Q1 2023 · Mar 31 | 2023-03-31 | 0.02 | 0.01 | +92.79% |
| Q4 2022 · Dec 31 | 2022-12-31 | 0.01 | −0.00 | −29.15% |
| Q1 2023 · Sep 30 | 2022-09-30 | 0.01 | −0.00 | −27.00% |
| Q4 2022 · Jun 30 | 2022-06-30 | 0.01 | −0.00 | −25.72% |
| Q3 2022 | 2022-03-31 | 0.01 | −0.00 | −24.40% |
| Q2 2022 | 2021-12-31 | 0.01 | −0.06 | −85.58% |
| Q1 2022 | 2021-09-30 | 0.01 | −0.18 | −94.21% |
| Q4 2021 | 2021-06-30 | 0.01 | −0.16 | −93.44% |
| Q3 2021 | 2021-03-31 | 0.01 | −0.17 | −93.26% |
| Q2 2021 | 2020-12-31 | 0.07 | −0.11 | −61.43% |
| Q1 2021 | 2020-09-30 | 0.19 | 0.02 | +11.25% |
| Q4 2020 | 2020-06-30 | 0.18 | — | — |
| Q3 2020 | 2020-03-31 | 0.18 | — | — |
| Q2 2020 | 2019-12-31 | 0.18 | — | — |
| Q1 2020 | 2019-09-30 | 0.17 | — | — |
Perspective Therapeutics debt-to-equity ratio trends
Between the periods ended 2020-06-30 and 2025-12-31, Perspective Therapeutics's debt-to-equity ratio decreased from 0.18 to 0.02, a change of −0.16. The latest reported quarter, Q2 2026, shows 0.01.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Perspective Therapeutics source filings ↗